-
-
-
-
-
-
-
Nektar Therapeutics (NKTR) Tops Q3 EPS by 185c
-
-
-
-
-
-
-
Nektar Therapeutics (NKTR) Misses Q1 EPS by 8c
-
-
-
-
-
-
-
Nektar Therapeutics (NKTR) Tops Q3 EPS by 2c
-
-
-
-
-
-
-
Nektar Therapeutics Reports First Quarter 2024 Financial Results
-
-
-
-
-
-
-
Nektar Therapeutics Reports Third Quarter 2023 Financial Results
-
-
-
-
-
-
-
Nektar Announces Promising New and Corrected Rezpegaldesleukin Efficacy Data Which Were Previously Reported in 2022 and Incorrectly Calculated by Former Collaborator Eli Lilly & Company
-
-
-
-
-
-
-
Nektar Therapeutics Reports Third Quarter 2022 Financial Results
-
1,199,633 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

